Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-phosphatidylserine monoclonal antibodies - Avid Bioservices

Next Previous
X
Search
Drug Profile

Research programme: anti-phosphatidylserine monoclonal antibodies - Avid Bioservices

Alternative Names: 2aG4; Anti-phosphatidylethanolamine monoclonal antibodies - Avid Bioservices; Anti-phospholipid monoclonal antibodies - Avid Bioservices; ch1N11; PGN-502; PGN-503; PGN-504; Truncated tissue factors - Avid Bioservices; Vascular targeting agents - Avid Bioservices

Latest Information Update: 02 Apr 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center; University of Texas Southwestern Medical Center
  • Developer Avid Bioservices; Peregrine Pharmaceuticals
  • Class Diagnostic agents; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Diagnostic imaging enhancers; Immunostimulants; Magnetic resonance imaging enhancers; Phosphatidylserine receptor antagonists; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Brain cancer; Cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Triple negative breast cancer

Most Recent Events

  • 18 Sep 2020 Oncologie is now called OncXerna Therapeutics
  • 28 Nov 2018 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (Parenteral)
  • 28 May 2018 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top